A Phase 1 Study of Autologous Memory-like Natural Killer (NK) Cell Immunotherapy with BHV-1100 (formerly KP1237) and IVIG followed by low dose IL-2 as Early Post-Autologous Transplant Consolidation in Minimal Residual Disease Positive, Multiple Myeloma (MM) Patients in First or Second Remission
ENROLLING
Trial ID:
NCT04634435 Protocol # :
20-120
Phase
I
Disease Sites
Multiple Myeloma
Principal Investigator
Bianchi, Giada
Site Research Nurses
Hogan, Sarah
Kendricken, Elizabeth
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #20-120
20-120